Neuphoria Therapeutics
NEUP
5 hedge funds and large institutions have $5.51M invested in Neuphoria Therapeutics in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$2.07M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$1.04M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$13.2K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.23K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LSM
1
Light Sky Macro
New York
| $2.45M | +$2.49M | +16,264 | New |
|
|
WP
2
Woodline Partners
San Francisco,
California
| $2.03M | +$2.07M | +13,495 | New |
|
|
BI
3
BVF Inc
San Francisco,
California
| $1.02M | +$1.04M | +6,748 | New |
|
|
4
UBS Group
Zurich,
Switzerland
| $13K | +$13.2K | +86 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $1K | +$1.23K | +8 | New |
|
NEUP Hedge Fund Activity: Q4 2021 in Review
5 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q4 2021, worth a combined $5.51M.
Buyers outnumbered sellers: 5 funds opened new NEUP positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $2.07M.
- 5 institutional investors held Neuphoria Therapeutics (NEUP) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $5.51M of Neuphoria Therapeutics stock for Q4 2021.
- 5 funds opened new Neuphoria Therapeutics positions in Q4 2021 and 0 closed out, a net change of +5 holders.
- The largest Neuphoria Therapeutics buyer in Q4 2021 was Woodline Partners, an estimated $2.07M added.
Based on aggregated 13F filings for Q4 2021.